Latest Breaking News On - Oregon health science university casey eye institute - Page 1 : comparemela.com

OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

BCVA gains of +5.5 letters at 24 months in Cohort 4 patients BCVA gains of +7.4 letters among Cohort 4 patients with extensive OpRegen bleb coverage of the GA lesion Maintenance or increases.

RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that 24 month results from patients enrolled in.

ARVO Foundation announces 2024 recipient of Genentech Career Development Award for Underrepresented Minority Emerging Vision Scientists

Rockville, Md. The Association for Research in Vision and Ophthalmology (ARVO) Foundation congratulates Diana C. Lozano, PhD, who was awarded the 2024 Genente

ARVO Foundation announces 2024 recipient of Genentech Career Development Award for Underrepresented Minority Emerging Vision Scientists

25 stories of Oregonians who inspired us in 2023